GeoVax Labs, Inc. (GOVX)
-OTC Markets 0.50 0.00(0.00%) 3:07PM EDT
| Prev Close: | 0.50 |
|---|
| Open: | 0.50 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.56 |
|---|
| Beta: | 1.48 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.43 - 0.50 |
|---|
| 52wk Range: | 0.43 - 1.01 |
|---|
| Volume: | 6,266 |
|---|
| Avg Vol (3m): | 23,241 |
|---|
| Market Cap: | 10.25M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.11 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- GEOVAX LABS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Tue, Jun 11)
- GEOVAX LABS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial Statements and EEDGAR Online(Wed, May 15)
- GEOVAX LABS, INC. FinancialsEDGAR Online Financials(Wed, May 8)
- 2013 Will be a Banner Year for GeoVaxZacks(Mon, May 6)
- 2013 Will be a Banner Year for GeoVaxZacks Small Cap Research(Mon, May 6)
- GeoVax Labs Reports 2013 First Quarter Financial Results and Provides Clinical Development UpdateMarketwired(Thu, May 2)
- GEOVAX LABS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Thu, May 2)
- GEOVAX LABS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 1)
- GEOVAX LABS, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Mar 18)
- GeoVax is On Track to Advance its HIV/AIDS Vaccine Programs in 2013Zacks(Wed, Mar 13)
- GeoVax is On Track to Advance its HIV/AIDS Vaccine Programs in 2013Zacks Small Cap Research(Wed, Mar 13)
- GEOVAX LABS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Tue, Mar 12)
- GeoVax Labs Reports 2012 Financial Results and ProgressMarketwired(Mon, Mar 11)
- GeoVax Labs Launches New Corporate WebsiteMarketwired(Wed, Jan 23)
- GeoVax (GOVX): Initiation with OutperformZacks(Wed, Jan 23)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 3.94 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.10 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
GeoVax Labs, Inc. operates as a biotechnology company. It focuses on developing vaccines that prevent and fight human immunodeficiency virus (HIV) infections that result in acquired immunodeficiency syndrome (AIDS).
View More 
1.35%